RecruitingPhase 2NCT05551208

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

A Prospective, Single-arm, Multicenter Phase Ⅱ Clinical Study of Fluzoparib Combined With Bevacizumab in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi

Sponsor

Chongqing University Cancer Hospital

Enrollment

42 participants

Start Date

Aug 15, 2022

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer

Summary

There are more and more PARPi(PARP inhibitors) resistance for ovarian cancer patients after previous use of PARP inhibitors. Basic studies have found that there is synergistic effect of bevacizumab combined with PARPi. Therefore we designed the study to include 42 ovarian cancer patients who had PARPi for at least half a year and then relapsed (platinum-sensitive, previously 1-3 lines of chemotherapy). After getting complete remission or partial remission with chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used for maintenance treatment. The progression-free survival, ORR, DCR, DoR, and safety were evaluated based on RECIST V1.1.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing the combination of two drugs — fluzoparib (a PARP inhibitor) and bevacizumab (an anti-blood vessel drug) — in women with ovarian cancer that has come back after prior treatment with PARP inhibitor drugs. **You may be eligible if...** - You have serous or endometrioid ovarian cancer confirmed by biopsy - You have had at least 1–3 platinum-based chemotherapy regimens after surgery - Your cancer progressed more than 6 months after your last chemotherapy cycle - You are between 18 and 75 years old with an ECOG score of 0–1 - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have previously used bevacizumab and it did not work - You have uncontrolled high blood pressure or a history of serious bleeding - You are pregnant or breastfeeding - Your blood counts or organ function are outside acceptable ranges Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGfluzopanib and bevacizumab

fluzopanib and bevacizumab were used for maintenance treatment

Locations(1)

Chongqing Cancer Hospital

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05551208

Related Trials

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT069150257 locations

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT057399814 locations

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779157 locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations